QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

COMPLETION OF SCHEME

---

1. INTRODUCTION

The Board of Directors ("**Board**") of QT Vascular Ltd. ("**Company**" or **"QT Vascula**r**"**) refers to the announcements on 2 March 2022, 22 March 2022, 11 May 2022, 19 May 2022, 1 June 2022, 24 June 2022, 29 June 2022, 5 July 2022, 14 July 2022, 20 July 2022 and 27 July 2022 in relation to the Scheme and the Scheme Document dated 1 June 2022.

Unless otherwise defined, all capitalised terms used herein shall have the same meanings ascribed in the Scheme Document.

2. COMPLETION OF SCHEME

Given all conditions in relation to the Scheme (including those set out in Appendix G of the Scheme Document and the announcements of the Company on 19 November 2021 and 11 May 2022) have been satisfied and the Court Order has been lodged with ACRA, the Scheme has therefore become effective and binding.

Accordingly, with the completion of the Scheme:

(a) the Proposed Restructuring has been completed, such that the Company has become a wholly-owned subsidiary of Quantum Healthcare Limited (**"Quantum Healthcare"**) and Entitled Shareholders of the Company now hold the shares of Quantum Healthcare, which are to be listed and quoted on the Catalist at 9:00 a.m. on 29 July 2022;

(b) the Transfer of Listing Status from the Company to Quantum Healthcare has been completed, and shares of Quantum Healthcare is to be listed and quoted on the Catalist at 9:00 a.m. on 29 July 2022;

(c) Quantum Healthcare has the same directors as those previously in the Company, comprising:

(i) Thomas Tan Gim Chua, as Chief Executive Officer, Executive Director and member of Nominating Committee of Quantum Healthcare;

(ii) Victor Ng Fook Ai, as Independent Non-Executive Chairman and member of Audit Committee, Nominating Committee and Remuneration Committee of Quantum Healthcare;

(iii) Sho Kian Hin, as Independent Director, chairman of Audit Committee and member of Remuneration Committee of Quantum Healthcare; and

(iv) Ng Boon Eng, as Independent Director, chairman of Nominating Committee and member of Audit Committee and Remuneration Committee of Quantum Healthcare,

and the same executive officers, comprising;

(A) Kelvin Tong, as Chief Financial Officer of Quantum Healthcare; and

(B) Dr Jimmy Gian Siong Lin, as Chief Operating Officer (Dental) of Quantum

Healthcare;

The Company wishes to update that Mr Momi Brosh, Chief Executive Officer of TriReme Medical, LLC, an indirect subsidiary of Quantum Healthcare, will no longer be considered an executive officer of Quantum Healthcare as TriReme Medical, LLC will not be a material or key operating entity of Quantum Healthcare Group;

(d) Quantum Healthcare has assumed all liabilities and obligations of the Company in connection with Proposed Options Variation and Proposed Awards Variation;

(e) Quantum Healthcare has adopted the Quantum Healthcare Share Issue Mandate; and

(f) the sponsor of Quantum Healthcare remains PrimePartners Corporate Finance Pte. Ltd..

Quantum Healthcare will also proceed with the Proposed Transfer of ADG, which involves the transfer of the 60% shares held by the Company in ADG to Quantum Healthcare, so that ADG will become a directly held subsidiary of Quantum Healthcare and carry on its Healthcare Business. The Proposed Transfer of ADG is expected to take place in August 2022, and Quantum Healthcare will update shareholders when the Proposed Transfer of ADG has been completed.

3. OTHER IMPORTANT DATES IN RELATION TO THE SCHEME

For ease of reference, the following important dates relating to the Scheme are set out below:

(a) **Date and time for commencement of trading of Quantum Healthcare Shares on the SGX-ST**

9:00 a.m. on 29 July 2022

(b) **Date of withdrawal of QT Vascular Shares / delisting of QT Vascular from the SGX-ST**

9:00 a.m. on 29 July 2022

Shareholders should note that that any in-principle approval given by the SGX-ST in connection with the Scheme is not to be taken as an indication of the merits of the Scheme, Quantum Healthcare Group nor Quantum Healthcare Shares.

BY ORDER OF THE BOARD

Thomas Tan Gim Chua
Chief Executive Officer
28 July 2022

*This announcement has been reviewed by Quantum Healthcare's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.